Dr. Puja Verma, Dr. Dipti Roy, Dr. Surbhi Suman


Iron deficiency anaemia is the commonest haematological disorder of pregnancy in India. In pregnant women intolerant to oral iron intravenous
iron in various forms is available. This study compares intravenous ferric carboxymaltose and iron sucrose in 100 pregnant women. . After therapy
the mean Hb at 2 weeks was 10.59 ± 0.73 and 11.61 ± 0.54 in IS and FCM group respectively. The mean Hb level at 4 weeks was 11.19 ± 0.8 g/dl and
12.01 ± 0.64 g/dl in IS and FCM group respectively. The mean MCV increased to 82.71 ±3.6 fl in 2 weeks and 84.61 ± 3.4 in 4 weeks in women
treated with iron sucrose. The rise in mean MCV was also seen in women in FCM group which was 86.76±3.1 fl after 2 weeks and 87.84±3.4 fl after
4 weeks. FCM was found to be better as it increased Hb levels in lesser number of doses and less number of hospital visits as compared to IS.


anaemia in pregnancy, ferric carboxymaltose, iron sucrose.

Full Text:



(1) Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJL. Comparative risk assessment collaborating group. Selected major risk factors and global and regional burden of disease. Lancet Lond Engl. 2002;360(9343):1347–1360. doi: 10.1016/S0140-6736(02)11403-6. [PubMed] [CrossRef] [Google Scholar]

(2) . WHO. Nutritional anemias. Report of a WHO scientific group. Geneva, World Health Organization, 1968. (WHO Technical Report Series, No. 405). Accessed 5 Nov 2017.

(3) CDC (1989) CDC criteria for anemia in children and childbearing-aged women. MMWR Morbidity and mortality weekly report. 138(22):400–404 [PubMed]

(4) Indian Council of Medical Research. Evaluation of the National Nutritional Anemia Prophylaxis Programme. An ICMR Task Force Study. New Delhi ICMR; 1989

(5) Kumar A. National nutritional anaemia control programme in India. Indian J Public Health. 1999;43:3–5. [PubMed] [Google Scholar]

(6) Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr. 1970;100(7):301–303. [PubMed] [Google Scholar]

(7) Pfenninger A, Schuller C, Christoph P, Surbek DSafety and efficacy of high-dose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia.j.peinat Med.2012 apr 2;40(4):397-402

(8) Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199(4):435. doi: 10.1016/j.ajog.2008.07.046. [PubMed] [CrossRef] [Google Scholar]

(9) Jose A., Mahey R., Sharma J. B., et al. Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy-randomised controlled trial. BMC Pregnancy and Childbirth. 2019;19(1):p. 54. doi: 10.1186/s12884-019-2200-3. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

(10) Christoph P., Schuller C., Studer H., Irion O., De Tejada B. M., Surbek D. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs iron sucrose. Journal of Perinatal Medicine. 2012;40(5):469–474. doi: 10.1515/jpm-2011-0231. [PubMed] [CrossRef] [Google Scholar]

(11) Naqash A., Ara R., Bader G. N. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anaemia: phase IV clinical trials. BMC Women’s Health. 2018;18(1):p. 6. doi: 10.1186/s12905-017-0506-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

(12) Shah S., Swapna K. A comparative study of efficacy and safety of intravenous Ferric Carboxymaltose versus intravenous Iron Sucrose in the treatment of Iron Deficiency Anaemia of pregnancy. IOSR Journal of Dental and Medical Sciences. 2018;17(9):13–17. [Google Scholar


  • There are currently no refbacks.